INCYTE CORP (INCY) Form 8-K — Jul 28, 2026

$INCYForm 8-KItems 2.02, 9.01Filed Jul 28, 2026, 7:02 AM ET0000879169-26-000053Original filing

Incyte Corporation reported second-quarter 2026 total revenue of $1.67 billion, a 38% increase year-over-year, and total net sales of $1.49 billion, up 40%. The growth was significantly driven by a $246 million one-time non-cash benefit related to a CMS settlement for Opzelura, alongside increased demand for Jakafi and the Hematology and Oncology portfolio. Based on these results, Incyte raised its full-year 2026 total net sales guidance to $5.13 billion to $5.26 billion. The company completed the acquisition of Vega Therapeutics for $1.25 billion upfront, adding latarcibart, a Phase 3 asset for von Willebrand disease, to its pipeline.

Key figures

Eps: $2.81
Revenue: $1.67 billion
Guidance: $5.13 - $5.26 billion
Net Income: $585.6 million
Cash Position: $4.5 billion
Deal Value Usd: $1.25 billion
Jakafi net sales: $817 million
Opzelura net sales: $450 million
Cms one time benefit: $246 million

Price after filing

1 day: +1.9%7 days: +5.4%30 days: +9.8%

Close on the filing date to close N calendar days later (from $116.69). Historical, not a forecast.

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.